Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells

XBP1 is a critical transcriptional activator of the unfolded protein response (UPR), which increases tumor cell survival under prolonged endoplasmic reticulum (ER) stress and hypoxic conditions.This study was designed to evaluate the immunogenicity of heteroclitic XBP1 unspliced (US)184–192 (YISPWILAV) and heteroclictic XBP1 spliced (SP)367–375 (YLFPQLISV) HLA-A2 peptides, and to characterize the specific activities of XBP1 peptides-specific cytotoxic T lymphocytes (XBP1-CTL) against breast cancer, colon cancer, and pancreatic cancer cells.The XBP1-CTL had upregulated expression of critical T cell markers and displayed HLA-A2-restricted and antigen-specific activities against breast cancer, colon cancer and pancreatic cancer cells. XBP1-CTL were enriched withCD45RO+ memory CTL, which showed high expression of critical T cell markers (CD28, ICOS, CD69, CD40L), cell proliferation and antitumor activities as compared to CD45RO− non-memory CTL. The effector memory (EM: CD45RO+CCR7−) subset had the highest level of cell proliferation while the central memory (CM: CD45RO+CCR7+) subset demonstrated enhanced functional activities (CD107a degranulation, IFNγ/IL-2 production) upon recognition of the respective tumor cells. Furthermore, both the EM and CM XBP1-CTL subsets expressed high levels of Th1 transcription regulators Tbet and Eomes. The highest frequencies of IFNγ or granzyme B producing cells were detected within CM XBP1-CTL subset that were either Tbet+ or Eomes+ in responding to the tumor cells.These results demonstrate the immunotherapeutic potential of a cocktail of immunogenic HLA-A2 specific heteroclitic XBP1 US184–192 and heteroclictic XBP1 SP367–375 peptides to induce CD3+CD8+ CTL enriched for CM and EM cells with specific antitumor activities against a variety of solid tumors.

[1]  S. Steinberg,et al.  Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[2]  Wen-feng Zhang,et al.  Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy. , 2013, Cancer letters.

[3]  Jingting Jiang,et al.  Higher numbers of T-bet+ intratumoral lymphoid cells correlate with better survival in gastric cancer , 2013, Cancer Immunology, Immunotherapy.

[4]  Amy S. Lee,et al.  The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies , 2013, Oncogene.

[5]  Parantu K. Shah,et al.  canEvolve: A Web Portal for Integrative Oncogenomics , 2013, PloS one.

[6]  H. Chung,et al.  Annals of the New York Academy of Sciences Unfolded Protein Response to Autophagy as a Promising Druggable Target for Anticancer Therapy , 2022 .

[7]  S. Rosenberg,et al.  The Stoichiometric Production of IL-2 and IFN-γ mRNA Defines Memory T Cells That Can Self-Renew After Adoptive Transfer in Humans , 2012, Science Translational Medicine.

[8]  Hiroaki Tanaka,et al.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.

[9]  K. Anderson,et al.  Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders , 2012, Clinical Cancer Research.

[10]  J. Larkin,et al.  A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma , 2012, Investigational New Drugs.

[11]  E. Yang,et al.  The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets , 2011, Nature Immunology.

[12]  M. Jenkins,et al.  Opposing signals from the Bcl6 transcription factor and the interleukin-2 receptor generate T helper 1 central and effector memory cells. , 2011, Immunity.

[13]  Nikhil S. Joshi,et al.  Increased Numbers of Preexisting Memory CD8 T Cells and Decreased T-bet Expression Can Restrain Terminal Differentiation of Secondary Effector and Memory CD8 T Cells , 2011, The Journal of Immunology.

[14]  L. Glimcher,et al.  Extensive pancreas regeneration following acinar-specific disruption of Xbp1 in mice. , 2011, Gastroenterology.

[15]  Jingting Jiang,et al.  T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract , 2011, Immunologic research.

[16]  N. Munshi,et al.  Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: A potential therapeutic application in multiple myeloma , 2011, Leukemia.

[17]  F. Marincola,et al.  gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. , 2011, The New England journal of medicine.

[18]  Randal J. Kaufman,et al.  Endoplasmic reticulum stress in liver disease. , 2011, Journal of hepatology.

[19]  M. White,et al.  Regulation of glucose homeostasis through a XBP-1–FoxO1 interaction , 2011, Nature Medicine.

[20]  A. Rogel,et al.  A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination , 2011, Cancer Immunology, Immunotherapy.

[21]  F. Sugawara,et al.  Inhibitory effect of somatostatin Peptide analogues on DNA polymerase activity and human cancer cell proliferation. , 2010, Anticancer research.

[22]  E. Wherry,et al.  Cutting Edge: The Transcription Factor Eomesodermin Enables CD8+ T Cells To Compete for the Memory Cell Niche , 2010, The Journal of Immunology.

[23]  P. Morel,et al.  T-bet and Eomesodermin Are Required for T Cell-Mediated Antitumor Immune Responses , 2010, The Journal of Immunology.

[24]  S. Jagannath,et al.  Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma , 2010, British journal of haematology.

[25]  Y. Yoo,et al.  Differential effects of resveratrol and novel resveratrol derivative, HS-1793, on endoplasmic reticulum stress-mediated apoptosis and Akt inactivation. , 2010, International journal of oncology.

[26]  S. Ramalingam,et al.  Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Bevan,et al.  Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. , 2010, Immunity.

[28]  D. Vesole,et al.  Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent , 2009, Expert opinion on investigational drugs.

[29]  K. Shin‐ya,et al.  Preventing the unfolded protein response via aberrant activation of 4E‐binding protein 1 by versipelostatin , 2009, Cancer science.

[30]  John Calvin Reed,et al.  Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities , 2008, Nature Reviews Drug Discovery.

[31]  Bin Jiang,et al.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.

[32]  Hui Yang,et al.  Growth inhibition of colon cancer cells by polyisoprenylated benzophenones is associated with induction of the endoplasmic reticulum response , 2008, International journal of cancer.

[33]  C. Melief,et al.  Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines , 2008, Nature Reviews Cancer.

[34]  S. Groshen,et al.  Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. , 2008, Cancer research.

[35]  R. Clarke,et al.  Human X‐Box binding protein‐1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  E. Thiel,et al.  CMV‐specific central memory T cells reside in bone marrow , 2007, European journal of immunology.

[37]  P. Walter,et al.  Signal integration in the endoplasmic reticulum unfolded protein response , 2007, Nature Reviews Molecular Cell Biology.

[38]  M. Neurath,et al.  The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer , 2007, Gut.

[39]  Dejan Juric,et al.  Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  T. Barrette,et al.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.

[41]  Hiderou Yoshida,et al.  ER stress and diseases , 2007, The FEBS journal.

[42]  A. Koong,et al.  Targeting XBP-1 as a novel anti-cancer strategy , 2006, Cancer biology & therapy.

[43]  W. Gerald,et al.  An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen , 2006, Oncogene.

[44]  Graham M Lord,et al.  T-bet is required for optimal proinflammatory CD4+ T-cell trafficking. , 2005, Blood.

[45]  E. Wherry,et al.  Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin , 2005, Nature Immunology.

[46]  T. Waldmann,et al.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[47]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[48]  R. Bonasio,et al.  Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. , 2005, Immunity.

[49]  A. Koong,et al.  XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. , 2004, Cancer research.

[50]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[51]  D. Carrasco,et al.  Identification of genes modulated in multiple myeloma using genetically identical twin samples. , 2004, Blood.

[52]  T. Waldmann,et al.  IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Gonzalez,et al.  Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. , 2003, Blood.

[54]  S. Szabo,et al.  Antigen-driven effector CD8 T cell function regulated by T-bet , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Hao Shen,et al.  Control of Effector CD8+ T Cell Function by the Transcription Factor Eomesodermin , 2003, Science.

[56]  L. Glimcher,et al.  XBP-1 Regulates a Subset of Endoplasmic Reticulum Resident Chaperone Genes in the Unfolded Protein Response , 2003, Molecular and Cellular Biology.

[57]  K. Mori,et al.  Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. , 2003, Journal of hepatology.

[58]  K. Mori,et al.  Distinct roles of activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded protein response. , 2002, The Biochemical journal.

[59]  K. Mori,et al.  XBP1 mRNA Is Induced by ATF6 and Spliced by IRE1 in Response to ER Stress to Produce a Highly Active Transcription Factor , 2001, Cell.

[60]  D. Fearon,et al.  Arrested Differentiation, the Self-Renewing Memory Lymphocyte, and Vaccination , 2001, Science.

[61]  P Vaupel,et al.  Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. , 2001, Seminars in oncology.

[62]  K. Mori.  Tripartite Management of Unfolded Proteins in the Endoplasmic Reticulum , 2000, Cell.

[63]  R. Kaufman,et al.  Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. , 1999, Genes & development.

[64]  M. Rep,et al.  Phenotypic and Functional Separation of Memory and Effector Human CD8+ T Cells , 1997, The Journal of experimental medicine.

[65]  G. Giaccone,et al.  Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. , 2010, European journal of cancer.

[66]  A. Koong,et al.  Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth. , 2010, Cancer research.